Review



recombinant mouse il-6 protein  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Bio-Techne corporation recombinant mouse il-6 protein
    Recombinant Mouse Il 6 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 605 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/custom%40406-ml%4041826695
    Average 96 stars, based on 605 article reviews
    recombinant mouse il-6 protein - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Cell Viability Assay:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Viability Assay:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Bicinchoninic Acid Protein Assay:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Incubation:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Clinical Proteomics:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Concentration Assay:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Recombinant:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Modification:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Genetically Modified:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant

    Mouse Assay:

    Article Title: Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
    Article Snippet: PrePrint: brief, nucleofected cells were activated with plate-bound anti-CD3 (1 μg/ml; BD Biosciences, cat. no. 553238) and anti CD28 (1μg/ml; BD Biosciences, cat. no. 557393) in the presence of IL6 (30 ng/ml; R&D Systems, cat. no. 406-ML), TGFβ1 (5 ng/ml; R&D Systems, cat. no. 240-B), IL7 (5 ng/ml; kindly provided by Associate Professor Alexander Mildner, inFLAMES/University of Turku), and neutralizing ant



    Similar Products

    96
    Bio-Techne corporation recombinant mouse il-6 protein
    Recombinant Mouse Il 6 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/custom%40406-ml%4041826695
    Average 96 stars, based on 1 article reviews
    recombinant mouse il-6 protein - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    R&D Systems mouse recombinant il 6
    Mouse Recombinant Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/us12606559-332-21-26
    Average 96 stars, based on 1 article reviews
    mouse recombinant il 6 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    R&D Systems mouse il 6
    Mouse Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/pmc13015212-100-37-41
    Average 96 stars, based on 1 article reviews
    mouse il 6 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Sino Biological recombinant mouse il 6
    Recombinant Mouse Il 6, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Mouse+IL6+%2F+Interleukin-6+Protein/pmc12907011-162-52-55
    Average 94 stars, based on 1 article reviews
    recombinant mouse il 6 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    R&D Systems recombinant il 6 protein
    Senescence-like TAMs are induced upon chemotherapy in vivo. (A) CD163⁺ TAMs were isolated from human breast cancer tissue obtained via needle biopsy (pre-treatment) and surgical resection (post-neoadjuvant chemotherapy). Isolated TAMs underwent proteomic profiling using LC-MS/MS. The dataset is downloaded from the PRIDE repository under accession PXD022673. (B) Gene Set Enrichment Analysis (GSEA) of proteomic data highlights significantly altered biological functions in TAMs following neoadjuvant chemotherapy. (C) GSEA reveals significant upregulation of cellular senescence signatures in TAMs isolated from ADM-treated orthotopic 4T1 tumors, compared to PBS-treated controls. The dataset is downloaded from the PRIDE repository under accession PXD022674. (D) IF analysis of p16 + F4/80 + and p21 + F4/80 + TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). Scale bar, 50 μm. (E) Real-time qPCR analysis of senescence-related genes ( Cdkn2a , Cdkn1a , and Trp53 ) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (F) Western blotting analysis of senescence markers (p16 and p21) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (G) ELISA quantification of senescence-associated secretory phenotype (SASP) markers (IL-1α, <t>IL-6,</t> CXCL1, TNF-α) in conditioned media from TAMs isolated from orthotopic 4T1 tumors treated with control or ADM ( n = 5). For statistical analyses, an unpaired two-tailed t-test was used. * P < 0.05, ** P < 0.01
    Recombinant Il 6 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/pmc13009420-59-0-6
    Average 96 stars, based on 1 article reviews
    recombinant il 6 protein - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    R&D Systems recombinant mouse il 6 protein
    Senescence-like TAMs are induced upon chemotherapy in vivo. (A) CD163⁺ TAMs were isolated from human breast cancer tissue obtained via needle biopsy (pre-treatment) and surgical resection (post-neoadjuvant chemotherapy). Isolated TAMs underwent proteomic profiling using LC-MS/MS. The dataset is downloaded from the PRIDE repository under accession PXD022673. (B) Gene Set Enrichment Analysis (GSEA) of proteomic data highlights significantly altered biological functions in TAMs following neoadjuvant chemotherapy. (C) GSEA reveals significant upregulation of cellular senescence signatures in TAMs isolated from ADM-treated orthotopic 4T1 tumors, compared to PBS-treated controls. The dataset is downloaded from the PRIDE repository under accession PXD022674. (D) IF analysis of p16 + F4/80 + and p21 + F4/80 + TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). Scale bar, 50 μm. (E) Real-time qPCR analysis of senescence-related genes ( Cdkn2a , Cdkn1a , and Trp53 ) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (F) Western blotting analysis of senescence markers (p16 and p21) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (G) ELISA quantification of senescence-associated secretory phenotype (SASP) markers (IL-1α, <t>IL-6,</t> CXCL1, TNF-α) in conditioned media from TAMs isolated from orthotopic 4T1 tumors treated with control or ADM ( n = 5). For statistical analyses, an unpaired two-tailed t-test was used. * P < 0.05, ** P < 0.01
    Recombinant Mouse Il 6 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/pm41802506-88-3-7
    Average 96 stars, based on 1 article reviews
    recombinant mouse il 6 protein - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Novus Biologicals il 6
    Senescence-like TAMs are induced upon chemotherapy in vivo. (A) CD163⁺ TAMs were isolated from human breast cancer tissue obtained via needle biopsy (pre-treatment) and surgical resection (post-neoadjuvant chemotherapy). Isolated TAMs underwent proteomic profiling using LC-MS/MS. The dataset is downloaded from the PRIDE repository under accession PXD022673. (B) Gene Set Enrichment Analysis (GSEA) of proteomic data highlights significantly altered biological functions in TAMs following neoadjuvant chemotherapy. (C) GSEA reveals significant upregulation of cellular senescence signatures in TAMs isolated from ADM-treated orthotopic 4T1 tumors, compared to PBS-treated controls. The dataset is downloaded from the PRIDE repository under accession PXD022674. (D) IF analysis of p16 + F4/80 + and p21 + F4/80 + TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). Scale bar, 50 μm. (E) Real-time qPCR analysis of senescence-related genes ( Cdkn2a , Cdkn1a , and Trp53 ) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (F) Western blotting analysis of senescence markers (p16 and p21) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (G) ELISA quantification of senescence-associated secretory phenotype (SASP) markers (IL-1α, <t>IL-6,</t> CXCL1, TNF-α) in conditioned media from TAMs isolated from orthotopic 4T1 tumors treated with control or ADM ( n = 5). For statistical analyses, an unpaired two-tailed t-test was used. * P < 0.05, ** P < 0.01
    Il 6, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/pm41765162-62-0-1
    Average 94 stars, based on 1 article reviews
    il 6 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    96
    R&D Systems hyper il 6
    Senescence-like TAMs are induced upon chemotherapy in vivo. (A) CD163⁺ TAMs were isolated from human breast cancer tissue obtained via needle biopsy (pre-treatment) and surgical resection (post-neoadjuvant chemotherapy). Isolated TAMs underwent proteomic profiling using LC-MS/MS. The dataset is downloaded from the PRIDE repository under accession PXD022673. (B) Gene Set Enrichment Analysis (GSEA) of proteomic data highlights significantly altered biological functions in TAMs following neoadjuvant chemotherapy. (C) GSEA reveals significant upregulation of cellular senescence signatures in TAMs isolated from ADM-treated orthotopic 4T1 tumors, compared to PBS-treated controls. The dataset is downloaded from the PRIDE repository under accession PXD022674. (D) IF analysis of p16 + F4/80 + and p21 + F4/80 + TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). Scale bar, 50 μm. (E) Real-time qPCR analysis of senescence-related genes ( Cdkn2a , Cdkn1a , and Trp53 ) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (F) Western blotting analysis of senescence markers (p16 and p21) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (G) ELISA quantification of senescence-associated secretory phenotype (SASP) markers (IL-1α, <t>IL-6,</t> CXCL1, TNF-α) in conditioned media from TAMs isolated from orthotopic 4T1 tumors treated with control or ADM ( n = 5). For statistical analyses, an unpaired two-tailed t-test was used. * P < 0.05, ** P < 0.01
    Hyper Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+il-6+protein/Recombinant+Mouse+IL-6+Protein/pm41671082-162-15-16
    Average 96 stars, based on 1 article reviews
    hyper il 6 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    Senescence-like TAMs are induced upon chemotherapy in vivo. (A) CD163⁺ TAMs were isolated from human breast cancer tissue obtained via needle biopsy (pre-treatment) and surgical resection (post-neoadjuvant chemotherapy). Isolated TAMs underwent proteomic profiling using LC-MS/MS. The dataset is downloaded from the PRIDE repository under accession PXD022673. (B) Gene Set Enrichment Analysis (GSEA) of proteomic data highlights significantly altered biological functions in TAMs following neoadjuvant chemotherapy. (C) GSEA reveals significant upregulation of cellular senescence signatures in TAMs isolated from ADM-treated orthotopic 4T1 tumors, compared to PBS-treated controls. The dataset is downloaded from the PRIDE repository under accession PXD022674. (D) IF analysis of p16 + F4/80 + and p21 + F4/80 + TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). Scale bar, 50 μm. (E) Real-time qPCR analysis of senescence-related genes ( Cdkn2a , Cdkn1a , and Trp53 ) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (F) Western blotting analysis of senescence markers (p16 and p21) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (G) ELISA quantification of senescence-associated secretory phenotype (SASP) markers (IL-1α, IL-6, CXCL1, TNF-α) in conditioned media from TAMs isolated from orthotopic 4T1 tumors treated with control or ADM ( n = 5). For statistical analyses, an unpaired two-tailed t-test was used. * P < 0.05, ** P < 0.01

    Journal: Cellular Oncology

    Article Title: Targeting senescence-like tumor-associated macrophages sensitizes chemotherapy in triple-negative breast cancer

    doi: 10.1007/s13402-026-01197-3

    Figure Lengend Snippet: Senescence-like TAMs are induced upon chemotherapy in vivo. (A) CD163⁺ TAMs were isolated from human breast cancer tissue obtained via needle biopsy (pre-treatment) and surgical resection (post-neoadjuvant chemotherapy). Isolated TAMs underwent proteomic profiling using LC-MS/MS. The dataset is downloaded from the PRIDE repository under accession PXD022673. (B) Gene Set Enrichment Analysis (GSEA) of proteomic data highlights significantly altered biological functions in TAMs following neoadjuvant chemotherapy. (C) GSEA reveals significant upregulation of cellular senescence signatures in TAMs isolated from ADM-treated orthotopic 4T1 tumors, compared to PBS-treated controls. The dataset is downloaded from the PRIDE repository under accession PXD022674. (D) IF analysis of p16 + F4/80 + and p21 + F4/80 + TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). Scale bar, 50 μm. (E) Real-time qPCR analysis of senescence-related genes ( Cdkn2a , Cdkn1a , and Trp53 ) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (F) Western blotting analysis of senescence markers (p16 and p21) in TAMs isolated from treatment-naïve and ADM-treated tumors ( n = 5). (G) ELISA quantification of senescence-associated secretory phenotype (SASP) markers (IL-1α, IL-6, CXCL1, TNF-α) in conditioned media from TAMs isolated from orthotopic 4T1 tumors treated with control or ADM ( n = 5). For statistical analyses, an unpaired two-tailed t-test was used. * P < 0.05, ** P < 0.01

    Article Snippet: Recombinant IL-6 protein was purchased from R&D systems (Cat. 406-ML).

    Techniques: In Vivo, Isolation, Liquid Chromatography with Mass Spectroscopy, Western Blot, Enzyme-linked Immunosorbent Assay, Control, Two Tailed Test

    IL-6, a key factor of SASP, mediates chemoresistance in TNBC. (A) Viability of 4T1 tumor cells treated for 48 h with conditioned medium (CM) from TAMs isolated from PBS- or ADM-treated orthotopic 4T1 tumors, with/without neutralizing antibodies against SASP factors (IL-1α, IL-6, CXCL1, and TNF-α). Viability measured by CCK-8 assay (OD 450 nm). (B) CCK-8 assay showing the viability of 4T1 tumor cells upon treatment of recombinant IL-6 for 48 h. (C) ELISA analysis of IL-6 levels in TEC, CAF, or TAMs isolated from treatment-naïve or ADM-treated tumors ( n = 5). (D) Schematic model showing ADM and anti-IL-6 in the 4T1 orthotopic tumor model. (E) Tumor growth curves and tumor biopsies following administration of PBS, ADM, anti-IL-6, and ADM + anti-IL-6 combination therapy ( n = 5 mice per group). (F) Real-time qPCR analysis of drug resistance- and stemness-associated genes ( Abcb1 , Abcc1 , Cd44 , Aldh1a1 , and Prom1 ) in 4T1 cells with indicated treatments; tocilizumab at 10 µg/ml and Stattic at 5 µM. For statistical analyses, two-way ANOVA with Tukey’s multiple comparisons ( B ), unpaired two-tailed t-test ( D ) or one-way ANOVA followed by Tukey’s post hoc test ( E ) was used. ** P < 0.01, *** P < 0.001, and **** P < 0.0001

    Journal: Cellular Oncology

    Article Title: Targeting senescence-like tumor-associated macrophages sensitizes chemotherapy in triple-negative breast cancer

    doi: 10.1007/s13402-026-01197-3

    Figure Lengend Snippet: IL-6, a key factor of SASP, mediates chemoresistance in TNBC. (A) Viability of 4T1 tumor cells treated for 48 h with conditioned medium (CM) from TAMs isolated from PBS- or ADM-treated orthotopic 4T1 tumors, with/without neutralizing antibodies against SASP factors (IL-1α, IL-6, CXCL1, and TNF-α). Viability measured by CCK-8 assay (OD 450 nm). (B) CCK-8 assay showing the viability of 4T1 tumor cells upon treatment of recombinant IL-6 for 48 h. (C) ELISA analysis of IL-6 levels in TEC, CAF, or TAMs isolated from treatment-naïve or ADM-treated tumors ( n = 5). (D) Schematic model showing ADM and anti-IL-6 in the 4T1 orthotopic tumor model. (E) Tumor growth curves and tumor biopsies following administration of PBS, ADM, anti-IL-6, and ADM + anti-IL-6 combination therapy ( n = 5 mice per group). (F) Real-time qPCR analysis of drug resistance- and stemness-associated genes ( Abcb1 , Abcc1 , Cd44 , Aldh1a1 , and Prom1 ) in 4T1 cells with indicated treatments; tocilizumab at 10 µg/ml and Stattic at 5 µM. For statistical analyses, two-way ANOVA with Tukey’s multiple comparisons ( B ), unpaired two-tailed t-test ( D ) or one-way ANOVA followed by Tukey’s post hoc test ( E ) was used. ** P < 0.01, *** P < 0.001, and **** P < 0.0001

    Article Snippet: Recombinant IL-6 protein was purchased from R&D systems (Cat. 406-ML).

    Techniques: Isolation, CCK-8 Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Two Tailed Test

    Mechanism model. In the TNBC microenvironment, chemotherapy induces cellular senescence in TAMs. These senescence-like TAMs develop a senescence-associated secretory phenotype (SASP), prominently IL-6 secretion. IL-6 signals through the IL-6R-STAT3 axis in TNBC cells, thus inducing genes related to drug resistance (e.g., ABC transporters) and cancer stemness ( Cd44 , Aldh1a1 , and Prom1 ), ultimately driving therapeutic resistance

    Journal: Cellular Oncology

    Article Title: Targeting senescence-like tumor-associated macrophages sensitizes chemotherapy in triple-negative breast cancer

    doi: 10.1007/s13402-026-01197-3

    Figure Lengend Snippet: Mechanism model. In the TNBC microenvironment, chemotherapy induces cellular senescence in TAMs. These senescence-like TAMs develop a senescence-associated secretory phenotype (SASP), prominently IL-6 secretion. IL-6 signals through the IL-6R-STAT3 axis in TNBC cells, thus inducing genes related to drug resistance (e.g., ABC transporters) and cancer stemness ( Cd44 , Aldh1a1 , and Prom1 ), ultimately driving therapeutic resistance

    Article Snippet: Recombinant IL-6 protein was purchased from R&D systems (Cat. 406-ML).

    Techniques: